Advisory Cmte. Endorses Cinryze Unanimously, But HAE Battle Continues

Even with a unanimous endorsement from FDA's Blood Products Advisory Committee, Lev Pharmaceuticals' hereditary angioedema candidate Cinryze has an uncertain future because of competitive pressure - as several companies are racing to win FDA's orphan drug exclusivity for HAE